Cargando…
Increased MYBL2 expression in aggressive hormone‐sensitive prostate cancer
Loss of the histone demethylase KDM5D (lysine‐specific demethylase 5D) leads to in vitro resistance of prostate cancer cells to androgen deprivation therapy (ADT) with and without docetaxel. We aimed to define downstream drivers of the KDM5D effect. Using chromatin immunoprecipitation sequencing (Ch...
Autores principales: | Yoshikawa, Yuki, Stopsack, Konrad H., Wang, Xin Victoria, Chen, Yu‐Hui, Mazzu, Ying Z., Burton, Foster, Chakraborty, Goutam, Rajanala, Sai Harisha, Hirani, Rahim, Nandakumar, Subhiksha, Lee, Gwo‐Shu Mary, Frank, David, Davicioni, Elai, Liu, Glenn, Carducci, Michael A., Azuma, Haruhito, Kantoff, Philip W., Sweeney, Christopher J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9718114/ https://www.ncbi.nlm.nih.gov/pubmed/36087093 http://dx.doi.org/10.1002/1878-0261.13314 |
Ejemplares similares
-
Methylation‐associated miR‐193b silencing activates master drivers of aggressive prostate cancer
por: Mazzu, Ying Z., et al.
Publicado: (2019) -
Ribonucleotide reductase small subunit M2 is a master driver of aggressive prostate cancer
por: Mazzu, Ying Z., et al.
Publicado: (2020) -
Prognostic and therapeutic significance of COP9 signalosome subunit CSN5 in prostate cancer
por: Mazzu, Ying Z., et al.
Publicado: (2022) -
Dynamic expression of SNAI2 in prostate cancer predicts tumor progression and drug sensitivity
por: Mazzu, Ying Z., et al.
Publicado: (2022) -
A MYBL2 complex for RRM2 transactivation and the synthetic effect of MYBL2 knockdown with WEE1 inhibition against colorectal cancer
por: Liu, Qian, et al.
Publicado: (2021)